Last update: April 3, 2018
Minimal risk for breastfeeding and infant.
An aminoglycoside antibiotic with similar characteristics and actions as neomycin.
Used topically at 1% in skin infections and 0.5% in ear and eye infections.
Given its practically zero intestinal absorption, it has been used orally for selective intestinal decontamination, preoperatively or in intensive care patients.
Since the last update we have not found published data on its excretion in breast milk.
he small dose and poor plasma absorption of most topical preparations (dermatological or otological) make it very unlikely that significant amounts will transfer into breastmilk, although following subconjunctival injection plasma levels of 5 micrograms/ml have been observed, similar to those obtained following intramuscular injection (Bron 1970).
The small dose and low plasma absorption of most topical preparations make it unlikely that a significant amount will transfer into breastmilk. In addition, its zero or very low oral bioavailability would make it difficult for it to transfer to infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
We do not have alternatives for D09AA01 since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM